Navigate BioPharma Services and RareCyte have partnered to launch a new multiplex spatial biology assay service for whole-slide imaging and analysis of tissue sections. The service, enabled by RareCyte's Orion platform, is developed to cater to versatile drug targets and therapeutic areas.

The aim of this partnership is to enhance the delivery of end-to-end spatial biology services for clinical and pharmaceutical entities internationally. The Orion platform will let Navigate BioPharma improve its customization capacity and depth of biomarker data interpretation, which is vital for medical decisions. These services can potentially support the investigation of various diseases, identification of diagnostic biomarkers, and studying the mechanism of action of immune therapies, enabling the analysis of a greater combination of biomarkers simultaneously, providing a thorough examination of the tumor microenvironment.

RareCyte is a precision biology company known for its involvement in spatial biology and liquid biopsy. Since launching its first commercial product, the CyteFinder Imaging Instrument in 2015, RareCyte has served academic medical centers, contract research organizations, and biopharmaceutical companies. The company's key products include the Orion Multiplex Imaging Instrument, the AccuCyte Sample Preparation System, and CyteFinder II Imaging Instrument.